GHK-Cu, BPC-157, TB-500 and KPV — why these four are researched together.
The KLOW stack combines four research peptides that keep appearing together in recovery literature. The logic isn't "more is better" — it's that each targets a distinct pathway in the same process.
A copper-binding tripeptide your body produces naturally, studied for collagen synthesis signalling and dermal remodelling. Levels decline notably with age. Full GHK-Cu guide →
A gastric-derived pentadecapeptide researched for angiogenesis and tissue-repair models. Full BPC-157 guide →
A thymosin beta-4 fragment studied for actin regulation and the movement of cells toward repair sites.
A tripeptide fragment of alpha-MSH, researched for anti-inflammatory signalling in gut and skin models.
Recovery research generally breaks into three problems: rebuilding structure, repairing tissue, and controlling inflammation. GHK-Cu addresses the first, BPC-157 and TB-500 the second from complementary angles, and KPV the third. Studying them together examines whether the pathways reinforce one another.
The name is a shorthand that emerged in the research community for this particular four-compound combination. It has no regulatory or scientific standing — it's simply what researchers call the grouping.
Every compound in the stack is supplied for laboratory research use only, each third-party tested with a published COA.